Dr. Grey AI

Triptorelin (Trelstar)

Peptide

Triptorelin is a synthetic decapeptide GnRH agonist. FDA-approved in 2000, available as 1-month (3.75mg), 3-month (11.25mg), and 6-month (22.5mg) formulations. Clinical trials show 97.5% achieve castrate testosterone by day 29 with 6-month formulation. 9-month survival significantly higher than leuprolide (97.0% vs 90.5%, p=0.033). Also approved for adjuvant breast cancer treatment.

Quick Answer

What it is

Triptorelin is a synthetic decapeptide GnRH agonist. FDA-approved in 2000, available as 1-month (3.75mg), 3-month (11.25mg), and 6-month (22.5mg) formulations.

Key findings

  • Grade A: Testosterone Suppression (Prostate Cancer)
  • Grade A: PSA Suppression (Prostate Cancer)
  • Grade A: Overall Survival (Prostate Cancer)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Triptorelin (Trelstar)

Quick Facts: Triptorelin (Trelstar)

  • Best Evidence:Grade A
  • Conditions Studied:2
  • Research Outcomes:10
  • Grade A Findings:6
  • Grade B Findings:2
  • Key Effect:Prostate Cancer
A6
B2
C1
D1
2 conditions · 10 outcomes

Detailed Outcomes

|
A
Testosterone Suppression
97.5% achieve castrate testosterone by day 29. Mean T of 12.8 ng/dL from month 2-12. Most potent GnRH agonist with lowest mean testosterone levels.
large↓Improves
A
PSA Suppression
Median PSA reduced by 96.4% at 12 months. Real-world data shows reduction from 117.9 to 8.5 ng/mL at 6 months.
large↓Improves
A
Overall Survival
9-month survival significantly higher than leuprolide (97.0% vs 90.5%; p=0.033). Low nadir testosterone associated with improved OS (p<0.001).
large↑Improves
A
Ovarian Function Suppression
Used in TEXT and SOFT trials for premenopausal breast cancer. Approved in EU and US for adjuvant treatment with tamoxifen or AI.
large↓Improves
A
Disease-Free Survival (Breast)
SOFT/TEXT trials showed OFS plus tamoxifen provides significant DFS benefit in premenopausal patients. HOBOE trial validated efficacy.
moderate↑Improves
A
Ovarian Preservation
GIM/PROMISE-GIM6 study: reduces chemotherapy-induced early menopause. Enables fertility preservation in young breast cancer patients.
moderate↑Improves
B
Anti-Cancer Activity
16 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↑Improves
B
Safety/Tolerability
5 human trials support this finding. Human clinical trial data available.
small↑Improves
C
Reproductive Outcomes
10 systematic reviews and preclinical studies support this finding. Evidence includes systematic reviews/meta-analyses. Primarily preclinical evidence.
moderate↑Improves
D
Hormone Levels
2 human trials support this finding. Human clinical trial data available.
small↑Improves

Research Citations (42)

Efficacy of Triptorelin Combined with Recombinant Human Growth Hormone (rhGH) on Serum Sex Hormones, Bone Age, and Clinical Outcomes in Girls with Precocious Puberty.
(2025)
PMID: 39998154
Testosterone nadir and clinical outcomes in patients with advanced prostate cancer: Post hoc analysis of triptorelin pamoate Phase III studies
(2024)
PMID: 38481666
PRIORITI: Phase 4 study of triptorelin or active surveillance in high-risk prostate cancer
(2024)
PMID: 38958195
GnRH analogue triptorelin acetate induces ovulation in jennies during oestrus.
(2024)
PMID: 38546114
A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty.
(2024)
PMID: 39412628
Triptorelin nanoparticle-loaded microneedles for use in assisted reproductive technology.
(2023)
PMID: 37387211
The efficacy and safety of triptorelin-therapy following conservative surgery for deep infiltrating endometriosis: A multicenter, prospective, non-interventional study in China.
(2022)
PMID: 35119037
Assessment of Two Formulations of Triptorelin in Chinese Patients with Endometriosis: A Phase 3, Randomized Controlled Trial.
(2022)
PMID: 35947347
Single injection of triptorelin or buserelin acetate in saline solution induces ovulation in mares the same as a single injection of hCG.
(2020)
PMID: 31930759
Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer
(2018)
PMID: 29551913

Related Peptides

Goserelin (Zoladex)

Peptide

2 shared conditions · 11 outcomes

Goserelin is a synthetic decapeptide GnRH agonist. FDA-approved in 1989, it is used for prostate cancer, breast cancer, and endometriosis. Clinical trials show 82% objective response in metastatic prostate cancer and 10-year survival rates of 42-87% depending on setting. Available as 3.6mg (monthly) and 10.8mg (3-month) subcutaneous implants.